120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
优化亚洲患者依诺肝素剂量：年龄和肾功能在达到目标抗 Xa 水平中的关键作用
Authors Peng W , Yang S, Dai Y, Zhao Z , Yang B
Received 26 November 2025
Accepted for publication 30 January 2026
Published 6 February 2026 Volume 2026:18 576067
DOI https://doi.org/10.2147/CPAA.S576067
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Arthur E. Frankel
Wenxing Peng,1 Shuran Yang,1,2 Ying Dai,3 Zinan Zhao,4,5 Bo Yang6
1Department of Pharmacy, Beijing Anzhen Hospital, Capital Medical University, Beijing, People’s Republic of China; 2School of Pharmaceutical Sciences, Capital Medical University, Beijing, People’s Republic of China; 3Department of Pharmacy, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China; 4Department of Pharmacy, Beijing Hospital; National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences Beijing, People’s Republic of China; 5Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing, People’s Republic of China; 6Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, People’s Republic of China
Correspondence: Bo Yang, Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, No. 2 Anzhen Road, Chaoyang District, Beijing, 100029, People’s Republic of China, Email yangbohoo@126.com
Objective: To investigate the roles of age and renal function in optimizing enoxaparin dosage for achieving target anti-Xa levels in Asian patients.
Methods: A total of 135 patients subjected to enoxaparin therapy were retrospectively enrolled. Baseline demographic characteristics, clinical indicators, and laboratory test results were collected. The distribution patterns of weight-adjusted doses and anti-Xa levels were analyzed. Dose-response curves were employed to evaluate the probability of achieving therapeutic anti-Xa levels in different age groups (< 80 years vs ≥ 80 years) and estimated glomerular filtration rate (eGFR) categories (eGFR < 60 mL/min vs ≥ 60 mL/min).
Results: The dose distribution revealed discrepancies between actual weight-adjusted doses and manufacturer-recommended doses in some patients. Age significantly influenced the attainment of target anti-Xa levels, whereas renal function exhibited no significant impact. Dose-response curves demonstrated that patients aged ≥ 80 years required lower doses to achieve 90– 95% target anti-Xa levels compared to those < 80 years. No significant difference was observed in target attainment between patients with eGFR < 60 mL/min and those with eGFR ≥ 60 mL/min.
Conclusion: Within the range of eGFR ≥ 30 mL/min/1.73 m2, advanced age, rather than mild-to-moderate renal impairment, emerged as the critical factor for achieving target anti-Xa levels with enoxaparin in Asian patients. Patients aged ≥ 80 years required lower doses compared to younger patients. These findings still need prospective validation.
Keywords: enoxaparin, Asian patients, anti-Xa levels, age, renal function
1Department of Pharmacy, Beijing Anzhen Hospital, Capital Medical University, Beijing, People’s Republic of China; 2School of Pharmaceutical Sciences, Capital Medical University, Beijing, People’s Republic of China; 3Department of Pharmacy, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China; 4Department of Pharmacy, Beijing Hospital; National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences Beijing, People’s Republic of China; 5Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing, People’s Republic of China; 6Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, People’s Republic of China
Correspondence: Bo Yang, Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, No. 2 Anzhen Road, Chaoyang District, Beijing, 100029, People’s Republic of China, Email yangbohoo@126.com
Objective: To investigate the roles of age and renal function in optimizing enoxaparin dosage for achieving target anti-Xa levels in Asian patients.
Methods: A total of 135 patients subjected to enoxaparin therapy were retrospectively enrolled. Baseline demographic characteristics, clinical indicators, and laboratory test results were collected. The distribution patterns of weight-adjusted doses and anti-Xa levels were analyzed. Dose-response curves were employed to evaluate the probability of achieving therapeutic anti-Xa levels in different age groups (< 80 years vs ≥ 80 years) and estimated glomerular filtration rate (eGFR) categories (eGFR < 60 mL/min vs ≥ 60 mL/min).
Results: The dose distribution revealed discrepancies between actual weight-adjusted doses and manufacturer-recommended doses in some patients. Age significantly influenced the attainment of target anti-Xa levels, whereas renal function exhibited no significant impact. Dose-response curves demonstrated that patients aged ≥ 80 years required lower doses to achieve 90– 95% target anti-Xa levels compared to those < 80 years. No significant difference was observed in target attainment between patients with eGFR < 60 mL/min and those with eGFR ≥ 60 mL/min.
Conclusion: Within the range of eGFR ≥ 30 mL/min/1.73 m2, advanced age, rather than mild-to-moderate renal impairment, emerged as the critical factor for achieving target anti-Xa levels with enoxaparin in Asian patients. Patients aged ≥ 80 years required lower doses compared to younger patients. These findings still need prospective validation.
Keywords: enoxaparin, Asian patients, anti-Xa levels, age, renal function